




“Bind-Engulf-Destroy”
NanoViricides
Incorporated

Stock Symbol:
NNVC
(NYSE American)

NV-387, A Broad-Spectrum Antiviral Presenting Revolutionary Strategies for Viral Infections

Presented by:
Anil R. Diwan, PhD,
President & Exec. Chairman
adiwan@nanoviricides.com
Mobile: +1 (203) 606 9180.

Presented at:
The NIBA's 153rd Investment Conference
on: October 7, 2026, 12:10am
Held at:
The Westin Beach Resort, Ft. Lauderdale, FL

1

Disclosure Statement

NanoViricides, Inc. is a NYSE-American listed publicly traded company (stock symbol: NNVC).

This is not an offering memorandum and should not be construed as such. It is provided as a non-confidential document for informational purposes only.

[NanoViricides, Inc.\(www.nanoviricides.com\)](http://www.nanoviricides.com) is a clinical stage company that is creating special purpose nanomaterials as therapeutics against a number of different viruses. The Company's novel nanoviricide® class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. All of our drug candidates are based on broad and exclusive worldwide licenses in perpetuity from TheraCour Pharma, Inc. for the development of drugs to combat viral infections of Human Coronaviruses, Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Herpes Simplex Viruses (HSV-1 and HSV-2), Varicella-Zoster Virus (VZV), Influenza and Asian Bird Flu viruses, Dengue viruses, Ebola/Marburg viruses, Japanese Encephalitis virus, viruses causing viral Conjunctivitis (a disease of the eye). The Company's technology is based on broad, exclusive, sub-licensable, perpetual field licenses to all drugs developed in the licensed field areas (virus indications) from TheraCour Pharma, Inc. The Company obtains additional licenses after determining that it intends to pursue a drug candidate in the licensed field into commercialization. The Company's business model is based on licensing technology from TheraCour Pharma Inc. for specific application verticals of specific viruses, covering all drugs for the licensed application, as established at its foundation in 2005.

This document contains forward-looking statements that reflect the current expectation of NanoViricides, Inc. (the "Company") regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements are "forward-looking statements" within the meaning of Section 27A of the Securities18 Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements.

The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company's expectations include, but are not limited to, those factors that are disclosed under the heading "Risk Factors" and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities.

Although it is not possible to predict or identify all such factors, they may include the following: demonstration and proof of principle in pre-clinical trials that a nanoviricide is safe and effective; successful development of our product candidates; our ability to seek and obtain regulatory approvals, including with respect to the indications we are seeking; the successful commercialization of our product candidates; and market acceptance of our products.

NV-387, A Broad-Spectrum Antiviral Presenting A Revolutionary Strategy for Viral Infections

★ NV-387 is Revolutionizing How to Fight DEADLY NOVEL VIRAL Outbreaks

Phase II - NV-387 ORAL Treatment for Ebola Bundibugyo > Started

Phase II - NV-387 ORAL Treatment for Mpox > Started

Phase II - NV-387 Treatment for Measles > Planning

★ Respiratory Viral Infections Treatment will be
Revolutionized by Empiric Treatment with NV-387
Just Like Respiratory **Bacterial** Infections Treatment
was Revolutionized by Broad-Spectrum Antibiotics

★ Nanoviricides TM Platform Technology with More To Give

NV-HHV-1 Treatment for Most Herpesviridae - HSV-1, HSV-2, VZV, (CMV, EBV, HHV6A/B, HHV-7, HHV-8)

NV-HIV-1 “Functional Cure,” for HIV/AIDS

NV-387 is Revolutionizing How to Fight Deadly NOVEL VIRAL Outbreaks Ebola/Marburg; Mpox Clade I, II; Measles; (SARS-CoV-2); ...

NOVEL VIRUS OUTBREAKS TODAY - NO TREATMENT IS AVAILABLE; - VACCINES, ANTIBODIES NOT MATCHED TO STRAIN IF AVAILABLE			
0	When New or Modified Virus Enters Localized Individuals But Goes Unnoticed - e.g. SARS-CoV-2; MPox Clade II; Measles; MPox Clade I; Ebola BDBV...	Response Time	Issues; Costs
1	National, Continental, Global Health Emergencies Are Declared	1 ~ 8 Weeks	Collab. Meetings (Standardized)
2	Finances are Mobilized	2 ~ 4 Months	Local ~\$500M, Regional ~\$5B, Global ~\$5 Trillion
3	Governments Focus on Outbreak Mitigating Public Health Responses Case Isolation; Treatment Centers; Travel Restrictions; Prior Vaccine (if any)-	starting ~ 4 weeks,	Majority of Costs
4	Scientific Bodies and Pharma Co's Insist On Developing - NEW Virus-Specific Antibodies, Vaccines, Traditional Chemical Drugs	~ 3 to 6 months	~10% to 20% of Costs. MCM available only after 1 Year, if at all. RESULTS MAY NOT HELP FOR NEXT EPIDEMIC!
4b	- Clinical Trials of (potentially previously failed) Nucleos(t)ide-Analogs, NEW Virus-Specific Antibodies, Vaccines, Traditional Chemical Drugs	~ + 9 months to 2 years (EUA)	
5	- Also Approach Require Scientific Bodies and Research Supply Co's to - Develop NEW Diagnostic Testing and Assay Kits for Viruses: - Rapid Antigen Tests (Diagnostic); PCR based Tests (Confirm and Quantitate); Rapid Antibody Tests (Surveillance)	~ 1 to 3 months	~1% to 2% of Cost. Test Kits available only after 3-6 Months.
	- Testing and Validation for Licensing of New Assays and Kits	~ 3 to 6 months (EUA)	

NV-387 is Revolutionizing How to Fight Deadly VIRAL Outbreaks Ebola/Marburg; Mpox Clade I, II; Measles; (SARS-CoV-2); ...

**NV-387 is Broad-Spectrum and Could be Deployed Empirically for
Early Response to Novel Viral Outbreaks (upon First approval)**

**NV-387 is the ONLY ORAL TREATMENT in Phase II Clinical Trial for the
TREATMENT of EBOLA BUNDIBUGYO in DRC TODAY!**

**NV-387 is the NON-TOXIC ORAL TREATMENT in Phase II Clinical Trial
for the TREATMENT of the SEVERE MPOX CLADE I in DRC TODAY!**

NV-387 is READY for Clinical Trials as a TREATMENT for MEASLES

Lead Clinical Phase II Drug NV-387 Alone Targets Market Size over \$25 Billion Plus!

NV-387 is Revolutionizing How to Fight Deadly VIRAL Outbreaks

Ebola/Marburg; Mpox Clade I, II; Measles; (SARS-CoV-2); ...

Virus	Situation
Ebola Bundibugyo	Novel Virus; No Current Treatment or Vaccine Declared PHEIC by WHO May 17, 2026. Currently Limited to DRC. Now Kenya? Over 8,400 Confirmed Cases; Over 4,200 Deaths. Crude CFR 48%, Infection Fatality Rate (IFR) ~67%. BSL4-field-constrained Isolation. Community Resistance. Travel Restrictions.
MPox Clade I	Clade Ib More Easily Transmissible. Children. Clade Ia/Ib far More Severe than Clade 2a/2b (Endemic in USA) Declared PHEIC by WHO August 14, 2024. Currently Endemic in DRC. BUT Cases Spiking in the USA. Over 29,000 cases have been reported in DRC, with over 800 deaths. From ~4% to ~8% IFR. Smallpox-approved Drug Failed Clinical Trials. In USA, 2-dose Jynneos vaccine. Efficacy not yet known.
Measles	No Treatments. Possibly Novel Viruses (Variants of Types B, D) in Different Parts of the World. But Still Respond to the Old ~1967-era Type A Vaccines (Mono-Serotypic, Multiple Genotypes). Globally Resurgent. Was Never Eliminated in Major Populous Parts of the World. Bangladesh 194,000 Cases; 1,000+ Deaths from Mar'26 to Sep'26. Europe, Canada, Mexico far More Cases than USA USA in 2025 - 2,289 confirmed cases; 3 deaths. In 2026 - 3,887 cases; 2 to 5 deaths.

Moreover, Imagine...
NV-387 is Revolutionizing Antiviral Therapy
Like Penicillin Did for Bacterial Infections

VIRUS INFECTION TREATMENT TODAY

1. Patient Stays Home 2-3 days.
2. If Serious, Patient Goes to Doctor
3. Doctor - “Must be Viral, Go Home and Relax!”
4. Also does Diagnostic Testing for Viruses
 1. Rapid Antibody tests
 2. PCR based Tests
5. 2-10 days.

Note: Treatment for Influenza Requires to be Given in <48hrs after Infection!

LIKE BACTERIAL INFECTIONS BEFORE PENICILLIN!

BACTERIAL INFECTIONS TREATMENT
REVOLUTIONIZED BY ANTIBIOTICS THERAPY!

1. Patient Stays Home 2-3 days.
2. If Serious, Patient Goes to Doctor
3. Doctor - “Looks Like Bacterial Infection”
4. Doctor Prescribes a Course of a Broad-Spectrum Antibiotic e.g. Amoxicillin
5. Patient takes antibiotics. Typically recovers in 3-5 days.
6. If serious bacteria found, Doctor alerts patient and changes therapy as necessary.

NV-387 is Broad-Spectrum and Could be Prescribed Empirically for Suspected Respiratory Viral Infections (upon approval)

NanoViricides Drugs Pipeline: Cure Most Viruses!

		Drug Substance	Indication	Lead Id.	Animal Efficacy Eficacy	IND-Enabling Studies	Phase I	Phase II	Phase III
1	Attack Re-Infection Cycle	NV-387	MPox / Smallpox						
			Ebola (BDBV)						
			RSV	NV-387 is a Revolutionary Broad-Spectrum Antiviral that Mimics the Host Cell Sulfated Proteoglycans (XSPG). Over 90% of Human Viruses Bind First to XSPG's to Infect. Virus Cannot Escape the Drug In Spite of Extensive Evolution.					
2			COVID						
4			Influenza						
5			Measles						
6		NV-HHV-1 Pan-HerpesVirus Drug Candidate	Shingles (VZV)			NV-HHV-1 Mimics the Invariant Binding Site of Herpesviruses on the host cellular receptor HVEM. It was shown to work against HSV-1, HSV-2, and VZV (Shingles, Chickenpox). It is expected to Work Against Most of the Rest of Herpesviruses (EBV, HCMV, HHV-6A&6B, HHV-7, KSHV). EBV causes Mononucleosis, Multiple Myeloma. Herpesviruses are linked to Alzheimer's.			
7			Cold Sores (HSV-1)						
8			Genital Ulcers (HSV-2)						
9		NV-HIV-1	HIV/AIDS			NV-HIV-1 Mimics the Invariant Binding Site of HIV on the host cellular receptor CD4.			
10*	Attack COMPLETE Virus LifeCycle	NV-387-g-X	Curing DNA Viruses			X and Y are Proprietary, Patentable Chemicals Designed to Block the Replication Part of the Lifecycle of the Virus, While NV-387 Itself Is Designed to Block the Re-Infection Part. Thus the Drugs NV-387-g-X and NV-387-g-Y Would Block the Complete Virus Lifecycle of DNA and RNA Viruses Respectively. ("g" Refers to Encapsulation of the Guest (X or Y) Within the NV-387 Nanomicelles.)			
11*		NV-387-g-Y	Curing RNA Viruses						
+		Several Additional R&D Programs in Progress							
Advanced Development Programs to Cure for Most DNA and RNA Viral Infections				By Attacking Both the “Re-Infection Cycle” and the “Replication Cycle” Parts to Achieve Complete Virus LifeCycle Inhibition And Thus Cure of Most Viruses.					

... NanoViricides Has Drug Candidates For Large Markets: WIN-WIN For Investor and Inventor

Virus Family	Nanoviricide Drug Candidate	Market Size, Global Estimated			PRV Eligible?
		2025 \$ Billions	CAGR	2030 \$ Billions	
RSV	NV-387	3.1	18%	7.0	-
Influenza; H5N1 Bird Flu	NV-387	5.0	8.35%	7.5	-
Coronaviruses	NV-387	2.0	?	2.7	-
Measles		1		1.3	YES
Ebola / Marburg		2		2.7	YES
Orthopox Viruses (Smallpox / MPox)	NV-387	1.5	?	2.3	YES
Shingles	NV-HHV-1	1	?	~2	-
HSV-1 “Cold Sores”, HSV-2 “Genital Ulcers”	NV-HHV-1, NV-HHV-2	2.9	8.1%	4.3	-
HIV/AIDS	NV-HIV-1	9.4	6.4%	12.8	-
Dengue, Chikengunya, Other Emerging and Novel Viruses	NV-387, Others	2	6.4%	2.7	YES
Overall		29.9		43.3	

NV-387 Alone Plays in a Market Size of Over \$25 Billion (2030)!

POC In Vivo Broad-Spectrum Activity: NV-387 Is Effective in Lethal Animal Models and is Superior/Equivalent to Existing Drugs & No Toxicity Against a Diverse Family of Viruses

Target Indication	Virus Family	Animal Model	% Survival Improvement
Pediatric RSV (Adults as well)	RSV RSV, A2	Balb-c Mice Lethal Lung Infection	NV-387, PO Led to Full Survival Ribavirin = 97% (Toxic)
Influenza A, Pandemic Influenzas (H1N1, H3N2), Bird Flu H5N1	Influenzas; H3N2 (A/California/ 2/2014)	Balb-c Mice Lethal Lung Infection	NV-387, IV = 100% NV-387, PO = 88% Oseltamivir, PO = 38% Peramivir, IV = 38% & Baloxavir, PO = 38%
Coronaviruses, COVID, SARS-CoV-1 & -2, MERS	Corona-viruses; hCoV-NL-63 (SARS-CoV-2 Surrogate)	Rat Lethal Lung Infection	NV-387, IV = 180% NV-387, PO = 68% Remdesivir/SBECD = 40%
Measles	Measles Virus; Measles MD-US	hSLAM+ki/Ifn-/- Mice Lethal Lung Infection	NV-387, PO = 226% Ribavirin = 200% (Toxic)
Smallpox	Orthopox Viruses; Ectromelia	SCID-Balb-c Lethal Lung Infection	NV-387, PO = 100% NV-387-m-T, PO = 157% Tecovirimat = 114%
Monkeypox	Orthopox Viruses; Ectromelia	SCID-Balb-c Lethal Dermal-Scored Infection	NV-387, PO = 75% NV-387-m-T, PO = 112% Tecovirimat = 75%
	* Notes:	* NV-387-m-T: NV-387 plus Tecovirimat improved effect over each dosed separately. * NV-387 Mechanism is Orthogonal to Existing Drugs in All Cases. * So this is a Huge Benefit.	

NanoViricides Superior to All Other Current Antiviral Technologies

MCM Technology 	Nanoviricides	Small Chemicals	Antibodies	Vaccines
Attribute 				
Resistance to Viral Escape?	YES. Drug Remains Active in Face of Changing Virus	NO. Not Amenable to Rapid New development	NO. Changing Virus Necessitates New Development	NO. Changing Virus Necessitates New Development
Broad Antiviral Activity Spectrum?	YES. “Tunable” from One to Multiple Virus Families	Limited by Natural Development of Resistant Variants	NO. Very Narrow Spectrum; Specific to Few Strains	NO. Very Narrow Spectrum; Specific to Few Strains
Flexibility in Routes of Administration (RoA’s)?	YES. Oral, Inhalation, Injection, Infusion, Nasal Spray, Cream/ Ointment	Some Oral, Some Infusions	NO. Infusions Required	NO. Mostly Injections, Some Oral, Nasal likely
Safe, Well Tolerated with No Side Reactions?	YES. No Reportable AEs in Phase I	Limited Safety and Tolerability	NO. Limitations Exist.	NO. Given to Large, Healthy Population
Can Treat All Subjects?	YES. Enabled by Strong Safety and Multiple RoA’s	NO. Limitations from DDI, Inherent Toxicities, etc.	NO. Limitations Exist.	NO. Limitations Exist.

Nanoviricides Platform Technology Solves the Most Important Problem in Antivirals:
Viruses are Highly Unlikely to Escape a NanoViricide Drug - by Design!

NanoViricides is a Unique Drug Developer Company with Its Own cGMP-Capable Manufacturing Capability

- 🌐 Discovery to Drug Product Capabilities In-House
 - 🌐 Nanomedicines Characterization Facility
 - 🌐 Virology BSL-2 Certified Lab
 - 🌐 Protect Proprietary Technology & Intellectual Property
- 🌐 Highly Customizable and Flexible Clinical Drug Product Pharma Manufacturing Capability
 - 🌐 Rapid Transfer from Lab Bench to cGMP Manufacture
 - 🌐 Significant Time and Cost Savings
 - 🌐 Skin Creams, Eye Drops, Gels, Injectables, Oral...
- 🌐 US Based Manufacture Drug Products for USA Govt & Commercial Market Entry = Revenues
- 🌐 Fully owned Facility With No Debt



Strong Executive Team

Anil R. Diwan, PhD
President & Exec. Chairman
Co-Founder

Led Uplisting to NYSE-Amer. in 2013
Raised Over \$120M
Co-Inventor of Nanoviricides & of
TheraCour Platforms.
25+ years Leadership & Entrepreneurial
experience. Key Patents, Several NIH
SBIR Awards
PhD (Rice), BTech (IITB)
Ranked 9th All India on JEE to IITs

Krishna Menon,
VMD, MRCS, PhD
Consulting Medical Officer

30+ Years of Pharmaceutical Industry
Drug Discovery & Pre-clinical
Regulatory Development
Eli Lilly President's Award

AZT, GemCitabine, Pemetrexed
(Alimta) Development
Eli-Lilly, Dana-Farber, Beth-Israel, Bayer
Alumnus

Meeta R. Vyas, MBA
CFO

30+ years Experience in Corporate
Performance Improvement, Finance,
M&A, EBITDA Growth...
Principal, The Gores Group;
CEO, Signature Brands, Inc. : Mr. Coffee;
Ran \$1B GE Appliances Division;
Consultant, McKinsey & Company

MBA (Finance, Columbia U), BS (MIT)

Jayant Tatake, PhD
VP, R&D

30+ Years of Pharmaceutical Industry
Experience in Drug Discovery, cGMP
Manufacturing, cGLP QA/QC, CRO,
Synthesis, Scale-up, Formulations.
Former QA Asst. Director,
InterPharm, Inc.
Co-Inventor of Nanoviricides &
TheraCour Platforms

PhD, UICT, Mumbai, India

Independent Board of Directors

Mak Jawadekar, PhD

35+ Years of Pharmaceutical Industry Experience,
Pharma Strategic Consultant. Previously at Pfizer, Inc.,
as Director, Portfolio Management & Analytics, and as
Vice President, Asia Colleague Resource Group, in
Pfizer Global R&D.

Business and Research experience in joint ventures,
alliance management, contracting, pharma R&D, drug
delivery, clinical supply manufacture, etc. Global
experience working with United States, Europe, India,
Japan, China.

Independent Board Member since February, 2020

Hon. Theodore “Todd” Rokita, JD

Presently Attorney General, State of Indiana. Former
US Rep. from Indiana (4 terms since 2010). Served on
several House Committees. Co-owner, Apex Benefits
Group, Inc. Extensive executive, team-building,
business strategy, and fiscal management expertise in
the private sector, alongside his public service
leadership experience. Serves or has served as a
Member of the Board of Directors of several
commercial and charitable institutions.

Independent Board Member since May, 2020

Brian M. Zucker, CPA

30+ years of experience as a CPA specializing in the
securities industry. A Partner at CFO Financial
Partners, LLC (<https://www.cfopartners.com/>). Also
serves as the CFO and Financial Operations Principal
for numerous broker dealers and hedge funds. Partner
at RRBB Accountants & Advisors. CFO of EIG Energy
Partners Capital Markets, LLC. Ex-Senior Consultant at
Deloitte Haskins & Sells and at Price Waterhouse. Mr.
Zucker holds several FINRA licenses.

Independent Board Member since November, 2020



“Nanotechnology-Enabled Targeted Viricides”
A Publicly Traded Company, “NNVC”
www.nanoviricides.com

Thank you for your attention and guidance.

Please address additional inquiries/correspondence to:

Scientific and Technical:

Anil R. Diwan, Ph.D.

Mobile Phone:

+1 (203) 606-9180

Email:

adiwan@nanoviricides.com

**President & Executive Chairman
NanoViricides, Inc.**

Office:

**1 Controls Drive
Shelton, CT 06484.**

Business, Finance & Contracts:

Meeta R. Vyas, MBA, SB

Mobile Phone:

+1 (203) 552-1125

Email:


mvyas@nanoviricides.com

**CFO
NanoViricides, Inc.**

Office:

**1 Controls Drive
Shelton, CT 06484.**

**Together We Can
Destroy Viruses**



NanoViricides Technology Salient Features

- Viruses Cannot Escape Nanoviricides Technology Drugs
 - Because any changed variant still uses the same virus-binding features on human cells that are copied by our drug
- Nanoviricides Technology Drugs work Independent of Patient Immune Status
 - Virus itself compromises immune status to gain foothold and cause disease
 - Decreased immune strength in population
 - More Immune-compromised Patients - late age, comorbidities such as diabetes, allergies, as well as infections such as HIV
- Usable Across All Population Segments - Safe and Biocompatible Nanoviricides Technology Drugs
 - From Infants, Children, Adolescents, Adults, to Geriatrics
 - From Patients with Normal Health to Patients with Severe Co-morbidities
 - No Liver, Kidney, Heart etc. Target Organ Toxicity from Nanoviricides Technology Drugs in General

Emperic Therapy of Viral Infections Made Feasible

- 🌐 NV-387, An SPG-Mimetic Nanoviricide is Designed to Work Against -
- 🌐 Over 90% of Human Pathogens, Known and Unknown
- 🌐 > 90% Human Pathogenic Viruses Use HSPG (Heparan-Sulfate Proteoglycan)
- 🌐 Human-to-Human Transmission Enhancement is Associated with Virus's HSPG Usage Effectiveness
- 🌐 >99% Viruses Use One or More of: Sulfated Proteoglycans, Sialylated Glycoproteins, Integrins, HyperMannose Receptors (Lectins)
- 🌐 Enable Initial Response to Novel Pandemics (Disease X?) in <30 day Window!

Some NV-387 Target Product Characteristics TRL 5+ : Phase I Healthy Subjects Completed Successfully

- 🌐 Oral: NV-387 Oral Gummies, Blister-Packed
- 🌐 Low Cost Solution: COGS Low, No Biologics
- 🌐 RT Storage and Distribution > 2 Yrs Stability
- 🌐 Ease of Administration - Dissolves in Mouth; No Water, No Swallowing!
- 🌐 Simple Self-Dosing 1x Daily or 2x Daily
- 🌐 Safe and Well Tolerated (Phase I) Means Minimal Medical Burden
- 🌐 No Safety Signals - No Monitoring Required
- 🌐 Short Term Prophylactic Available:
Nasal Spray, I.M. Injection, I.P. Injection
- 🌐 Available: (Hospitalized) I.V. Infusion, Inhalation (nebulizer) for Deep Lung

How Does NanoViricides Technology Achieve All This Magic?

Later!

NanoViricides Regulatory Developments

NV-387 Clinical: Successful Phase I Completed	NV-387 Phase II in MPox Patients in DRC
- Non-Clinical Studies Completed - GMP Manufacture of Drug Substance Implemented - GMP Manufacture of Drug Product Implemented - CMC In-Process-Controls and Critical Quality Attributes Identified and Implemented - Characterization of Drug Substance & Drug Product, Impurities Determination, Assays - Completed - Phase I in Healthy Subjects Completed in India - No Dropouts, No reported AE's/SAE's No Signals (i.e. Safe and Well Tolerated) using: - Blood Chemistry, Target Organ Assays, Clinical. - CSR Submission Imminent	- Rolling CTA Filing Completed - Initial Approval pre-Submission Received, May 2025 - Approval to Start Dosing Received, November 2025 - Site Logistics in Progress - Drug Product Manufacturing Completed - At Our Own cGMP Manufacturing facility
	NV-387 Phase II for All Viral Acute/Severe Respiratory Infections (V-ARI, V-SARI) in India - Planning
	Emperic Treatment Regardless of Virus - Influenzas, RSV, COVID, Other Seasonal Viruses - Single Innovative, Adaptive Phase II Design to Answer Many Questions at Once at Low Cost

US FDA: Orphan Drug Designation (ODD) Applications Completed
- Smallpox (Bio-threat) - MPox (Endemic) - Measles (Emerging, Endemic)

US FDA Planned Activities*	
Rare Pediatric Disease Drug Designation > NV-387 Measles - Priority review Voucher ~\$200-250 Million	Pre-IND, IND for 2026-2027 - Measles - MPox (Endemic) - Smallpox (Bio-threat)
* : Based on Available Resources	

About NanoViricides, Inc.

- 🌐 Founded in USA with Inventors and Inventions in USA
- 🌐 Clinical Stage Pharma Company with Unique Nanomedicines Technology
- 🌐 NV-387 Successfully Completed Phase I in Healthy Subjects in India
- 🌐 Phase II in DRC to Treat MPox Soon
- 🌐 Fully USA-Based On-Shore cGMP Manufacturing of Drug Substances and Drug Products
- 🌐 Public Company, Listed on NYSE-Amer. since 2013 (Stock Symbol NNVC), Founded in 2005
- 🌐 Self-Sufficient Through Clinical Drug Product Supply
- 🌐 Animal Studies and cGLP Non-Clinical Studies Outsourced (USA Labs)
- 🌐 Raised Over \$170 Million Since Inception - Equity Based. No External Debt.

Intellectual Property - NanoViricides Has Complete Freedom to Operate

- All of the intellectual property has been developed internally by scientists at AllExcel, Inc., Team led by Dr. Anil R. Diwan
- TheraCour Pharma, Inc., founded and led by Dr. Diwan, contractually holds said nanomedicines IP of AllExcel, Inc.
- NanoViricides has a Perpetual, Exclusive, Sub-licensable License from TheraCour for All Products and Derivatives Discussed


- International Patents (PCT) have been filed and issued since 2006 and 2007 on the basic compositions of matter and use for encapsulation, anticancer, antiviral, and other applications.
- Two new PCT applications have been filed for the new innovations, and COVID-related drug applications in ca. 2020 and 2021.
- A new PCT application is in preparation.
- Additional patents will be filed as the developments progress further.
- Patents cover Compositions of Matter, Methods of Preparation, Synthesis, Manufacture, Isolation, Purification, Formulation, and Uses of Articles of Manufacture.

Here Is
How NanoViricides Technology
Achieves All This Magic

NanoViricides Platform Technology => Novel Antiviral Mechanism of Action


Schematic Structure

- Nanoviricide Homopolymer
- PEG based- RES protection
- Lipid pendants- Shape-shift
- Biomimetic
- Addressing - Antivirals that Mimic Cell-Side Sites
- Nano-scale “Velcro” Effect
- Lipid Fusion
- Encapsulation




Cell-Mimicking Nanomachines that Seek to Bind, Engulf and Destroy a Virus Particle Without Immune System Assistance


A Virus Uses Specific Cellular Receptor(s).
Viral Coat Protein Mutates Readily;



But Binds to the Same Site(s) on Its Cellular Receptor(s).



Attacking the Virus Using Its Own, Conserved, Cell-Binding Features:
Multi-point, Multi-targeted Therapeutics



- A nanoviricide Binds the Virus Particle at Multiple Points, “NanoVelcro” Effect (Stages #1,2,3)
- Engulfment of the Virus Particle by “Shape-shifting” Nanoviricide Micelle would Render the Virus Particle Incapable of Infecting Cell (stage #4)



“Nanotechnology-Enabled Targeted Viricides”
A Publicly Traded Company, “NNVC”
www.nanoviricides.com

Again, Thank you for your attention and guidance.

Please address additional inquiries/correspondence to:

Scientific and Technical:

Anil R. Diwan, Ph.D.

Mobile Phone:

+1 (203) 606-9180

Email:

adiwan@nanoviricides.com

**President & Executive Chairman
NanoViricides, Inc.**

Office:

**1 Controls Drive
Shelton, CT 06484.**

Business, Finance & Contracts:

Meeta R. Vyas, MBA, SB

Mobile Phone:

+1 (203) 552-1125

Email:

mvyas@nanoviricides.com

**CFO
NanoViricides, Inc.**

Office:

**1 Controls Drive
Shelton, CT 06484.**

**Together We Can
Destroy Viruses**

